Cadence launches OFIRMEV discomfort medicine in the U.S. Cadence Pharmaceuticals, Inc.S. Meals and Medication Administration accepted OFIRMEV in November 2010 for the management of mild to moderate pain, the management of moderate to serious discomfort with adjunctive opioid analgesics, and the reduction of fever.S. Related StoriesInner ear harm human brain warnings from nerve cellsAddressing standard of living needs in prostate malignancy: an interview with Professor Louis DenisNew UCLA research talks about primary care medical home in reducing childrens' repeat appointments to hospitalsThe national launch of OFIRMEV has been supported by 147 medical center sales specialists and 13 field medical science liaisons.S. Are stocked and accepting orders from hospitals fully.That’s down about 2 million from an earlier CBO report and displays the CBO's calculations that more folks will qualify for exemptions from the Affordable Care Action's requirements . Almost all 30 million nonelderly People in america who are uninsured will be exempt from the individual coverage mandate in medical care law in 2016, the agencies reported Wednesday. All told, about 4 million people will pay a penalty because they’re uninsured in that twelve months . In a new analysis, the Congressional Spending budget Office said only 4 million of the 30 million who are expected to become uninsured in 2016 can pay a fine.